4ni7 - Revision history

OCA at 16:57, 20 September 2023

OCA — Wed, 20 Sep 2023 16:57:38 GMT

←Older revision		Revision as of 16:57, 20 September 2023
Line 4:		Line 4:
	== Structural highlights ==		== Structural highlights ==
	<table><tr><td colspan='2'>[[4ni7]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4NI7 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4NI7 FirstGlance]. <br>		<table><tr><td colspan='2'>[[4ni7]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4NI7 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4NI7 FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=2JU:2-DEOXY-5-[(NAPHTHALEN-1-YLMETHYL)CARBAMOYL]URIDINE+5-(DIHYDROGEN+PHOSPHATE)'>2JU</scene>, <scene name='pdbligand=A2M:2-O-METHYLADENOSINE+5-(DIHYDROGEN+PHOSPHATE)'>A2M</scene>, <scene name='pdbligand=DUZ:5-(BENZYLCARBAMOYL)-2-DEOXYURIDINE+5-(DIHYDROGEN+PHOSPHATE)'>DUZ</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=OMC:O2-METHYLYCYTIDINE-5-MONOPHOSPHATE'>OMC</scene>, <scene name='pdbligand=OMG:O2-METHYLGUANOSINE-5-MONOPHOSPHATE'>OMG</scene>, <scene name='pdbligand=UPE:2-DEOXY-5-[(2-PHENYLETHYL)CARBAMOYL]URIDINE+5-(DIHYDROGEN+PHOSPHATE)'>UPE</scene></td></tr>	+	</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models\|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution\|Resolution]] 2.4Å</td></tr>
		+	<tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=2JU:2-DEOXY-5-[(NAPHTHALEN-1-YLMETHYL)CARBAMOYL]URIDINE+5-(DIHYDROGEN+PHOSPHATE)'>2JU</scene>, <scene name='pdbligand=A2M:2-O-METHYLADENOSINE+5-(DIHYDROGEN+PHOSPHATE)'>A2M</scene>, <scene name='pdbligand=DUZ:5-(BENZYLCARBAMOYL)-2-DEOXYURIDINE+5-(DIHYDROGEN+PHOSPHATE)'>DUZ</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=OMC:O2-METHYLYCYTIDINE-5-MONOPHOSPHATE'>OMC</scene>, <scene name='pdbligand=OMG:O2-METHYLGUANOSINE-5-MONOPHOSPHATE'>OMG</scene>, <scene name='pdbligand=UPE:2-DEOXY-5-[(2-PHENYLETHYL)CARBAMOYL]URIDINE+5-(DIHYDROGEN+PHOSPHATE)'>UPE</scene></td></tr>
	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4ni7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ni7 OCA], [https://pdbe.org/4ni7 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4ni7 RCSB], [https://www.ebi.ac.uk/pdbsum/4ni7 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4ni7 ProSAT]</span></td></tr>		<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4ni7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ni7 OCA], [https://pdbe.org/4ni7 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4ni7 RCSB], [https://www.ebi.ac.uk/pdbsum/4ni7 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4ni7 ProSAT]</span></td></tr>
	</table>		</table>

OCA at 08:29, 11 January 2023

OCA — Wed, 11 Jan 2023 08:29:44 GMT

←Older revision		Revision as of 08:29, 11 January 2023
Line 1:		Line 1:

	==Crystal structure of human interleukin 6 in complex with a modified nucleotide aptamer (SOMAMER SL1025)==		==Crystal structure of human interleukin 6 in complex with a modified nucleotide aptamer (SOMAMER SL1025)==
-	<StructureSection load='4ni7' size='340' side='right' caption='[[4ni7]], [[Resolution\|resolution]] 2.40Å' scene=''>	+	<StructureSection load='4ni7' size='340' side='right'caption='[[4ni7]], [[Resolution\|resolution]] 2.40Å' scene=''>
	== Structural highlights ==		== Structural highlights ==
-	<table><tr><td colspan='2'>[[4ni7]] is a 2 chain structure with sequence from [~~http~~://en.wikipedia.org/wiki/~~Human Human~~]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4NI7 OCA]. For a <b>guided tour on the structure components</b> use [~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4NI7 FirstGlance]. <br>	+	<table><tr><td colspan='2'>[[4ni7]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Homo_sapiens Homo sapiens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4NI7 OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4NI7 FirstGlance]. <br>
-	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"~~><scene name='pdbligand=NA:SODIUM+ION'>NA</scene></td></tr>~~	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=2JU:2-DEOXY-5-[(NAPHTHALEN-1-YLMETHYL)CARBAMOYL]URIDINE+5-(DIHYDROGEN+PHOSPHATE)'>2JU</scene>, <scene name='pdbligand=A2M:2-O-METHYLADENOSINE+5-(DIHYDROGEN+PHOSPHATE)'>A2M</scene>, <scene name='pdbligand=DUZ:5-(BENZYLCARBAMOYL)-2-DEOXYURIDINE+5-(DIHYDROGEN+PHOSPHATE)'>DUZ</scene>, <scene name='pdbligand=NA:SODIUM+ION'>NA</scene>, <scene name='pdbligand=OMC:O2-METHYLYCYTIDINE-5-MONOPHOSPHATE'>OMC</scene>, <scene name='pdbligand=OMG:O2-METHYLGUANOSINE-5-MONOPHOSPHATE'>OMG</scene>, <scene name='pdbligand=UPE:2-DEOXY-5-[(2-PHENYLETHYL)CARBAMOYL]URIDINE+5-(DIHYDROGEN+PHOSPHATE)'>UPE</scene></td></tr>
-	~~<tr~~ id~~='NonStdRes'><td class~~="~~sblockLbl"><b>[[Non-Standard_Residue\|NonStd Res:]]</b></td><td class="sblockDat~~"><scene name='pdbligand=2JU:2-DEOXY-5-[(NAPHTHALEN-1-YLMETHYL)CARBAMOYL]URIDINE+5-(DIHYDROGEN+PHOSPHATE)'>2JU</scene>, <scene name='pdbligand=A2M:2-O-METHYLADENOSINE+5-(DIHYDROGEN+PHOSPHATE)'>A2M</scene>, <scene name='pdbligand=DUZ:5-(BENZYLCARBAMOYL)-2-DEOXYURIDINE+5-(DIHYDROGEN+PHOSPHATE)'>DUZ</scene>, <scene name='pdbligand=OMC:O2-METHYLYCYTIDINE-5-MONOPHOSPHATE'>OMC</scene>, <scene name='pdbligand=OMG:O2-METHYLGUANOSINE-5-MONOPHOSPHATE'>OMG</scene>, <scene name='pdbligand=UPE:2-DEOXY-5-[(2-PHENYLETHYL)CARBAMOYL]URIDINE+5-(DIHYDROGEN+PHOSPHATE)'>UPE</scene>~~</td></tr>~~	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4ni7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ni7 OCA], [https://pdbe.org/4ni7 PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4ni7 RCSB], [https://www.ebi.ac.uk/pdbsum/4ni7 PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4ni7 ProSAT]</span></td></tr>
-	~~<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">IL6, IFNB2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])~~</td></tr>	+
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[~~http~~://~~oca~~.~~weizmann.ac.il/oca-docs~~/fgij/fg.htm?mol=4ni7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ni7 OCA], [~~http~~://pdbe.org/4ni7 PDBe], [~~http~~://www.rcsb.org/pdb/explore.do?structureId=4ni7 RCSB], [~~http~~://www.ebi.ac.uk/pdbsum/4ni7 PDBsum]</span></td></tr>	+
	</table>		</table>
	== Disease ==		== Disease ==
-	[~~[http~~://www.uniprot.org/uniprot/IL6_HUMAN IL6_HUMAN]] Genetic variations in IL6 are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:[~~http~~://omim.org/entry/604302 604302]]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis. Note=A IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in HIV-infected men.	+	[https://www.uniprot.org/uniprot/IL6_HUMAN IL6_HUMAN] Genetic variations in IL6 are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:[https://omim.org/entry/604302 604302]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis. Note=A IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in HIV-infected men.
	== Function ==		== Function ==
-	[~~[http~~://www.uniprot.org/uniprot/IL6_HUMAN IL6_HUMAN]] Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation Acts on B-cells, T-cells, hepatocytes, hematopoietic progenitor cells and cells of the CNS. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance.	+	[https://www.uniprot.org/uniprot/IL6_HUMAN IL6_HUMAN] Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation Acts on B-cells, T-cells, hepatocytes, hematopoietic progenitor cells and cells of the CNS. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance.
	<div style="background-color:#fffaf0;">		<div style="background-color:#fffaf0;">
	== Publication Abstract from PubMed ==		== Publication Abstract from PubMed ==
Line 24:		Line 22:

	==See Also==		==See Also==
-	*[[Interleukin\|Interleukin]]	+	*[[Interleukin 3D structures\|Interleukin 3D structures]]
	== References ==		== References ==
	<references/>		<references/>
	__TOC__		__TOC__
	</StructureSection>		</StructureSection>
-	[[Category: ~~Human~~]]	+	[[Category: Homo sapiens]]
-	[[Category: Clifton~~, M C~~]]	+	[[Category: Large Structures]]
-	[[Category: Davies, D]]	+	[[Category: Clifton MC]]
-	[[Category: Edwards, T]]	+	[[Category: Davies D]]
-	[[Category: Gelinas, A]]	+	[[Category: Edwards T]]
-	[[Category: Jarvis, T]]	+	[[Category: Gelinas A]]
-	~~[[Category: Cytokine-dna complex]]~~	+	[[Category: Jarvis T]]
-	~~[[Category: Interleukin-6~~]]	+

OCA at 08:14, 1 June 2016

OCA — Wed, 01 Jun 2016 08:14:09 GMT

←Older revision		Revision as of 08:14, 1 June 2016
Line 1:		Line 1:
		+
	==Crystal structure of human interleukin 6 in complex with a modified nucleotide aptamer (SOMAMER SL1025)==		==Crystal structure of human interleukin 6 in complex with a modified nucleotide aptamer (SOMAMER SL1025)==
	<StructureSection load='4ni7' size='340' side='right' caption='[[4ni7]], [[Resolution\|resolution]] 2.40Å' scene=''>		<StructureSection load='4ni7' size='340' side='right' caption='[[4ni7]], [[Resolution\|resolution]] 2.40Å' scene=''>
Line 6:		Line 7:
	<tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue\|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=2JU:2-DEOXY-5-[(NAPHTHALEN-1-YLMETHYL)CARBAMOYL]URIDINE+5-(DIHYDROGEN+PHOSPHATE)'>2JU</scene>, <scene name='pdbligand=A2M:2-O-METHYLADENOSINE+5-(DIHYDROGEN+PHOSPHATE)'>A2M</scene>, <scene name='pdbligand=DUZ:5-(BENZYLCARBAMOYL)-2-DEOXYURIDINE+5-(DIHYDROGEN+PHOSPHATE)'>DUZ</scene>, <scene name='pdbligand=OMC:O2-METHYLYCYTIDINE-5-MONOPHOSPHATE'>OMC</scene>, <scene name='pdbligand=OMG:O2-METHYLGUANOSINE-5-MONOPHOSPHATE'>OMG</scene>, <scene name='pdbligand=UPE:2-DEOXY-5-[(2-PHENYLETHYL)CARBAMOYL]URIDINE+5-(DIHYDROGEN+PHOSPHATE)'>UPE</scene></td></tr>		<tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue\|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=2JU:2-DEOXY-5-[(NAPHTHALEN-1-YLMETHYL)CARBAMOYL]URIDINE+5-(DIHYDROGEN+PHOSPHATE)'>2JU</scene>, <scene name='pdbligand=A2M:2-O-METHYLADENOSINE+5-(DIHYDROGEN+PHOSPHATE)'>A2M</scene>, <scene name='pdbligand=DUZ:5-(BENZYLCARBAMOYL)-2-DEOXYURIDINE+5-(DIHYDROGEN+PHOSPHATE)'>DUZ</scene>, <scene name='pdbligand=OMC:O2-METHYLYCYTIDINE-5-MONOPHOSPHATE'>OMC</scene>, <scene name='pdbligand=OMG:O2-METHYLGUANOSINE-5-MONOPHOSPHATE'>OMG</scene>, <scene name='pdbligand=UPE:2-DEOXY-5-[(2-PHENYLETHYL)CARBAMOYL]URIDINE+5-(DIHYDROGEN+PHOSPHATE)'>UPE</scene></td></tr>
	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">IL6, IFNB2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>		<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">IL6, IFNB2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
-	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ni7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ni7 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4ni7 RCSB], [http://www.ebi.ac.uk/pdbsum/4ni7 PDBsum]</span></td></tr>	+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ni7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ni7 OCA], [http://pdbe.org/4ni7 PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4ni7 RCSB], [http://www.ebi.ac.uk/pdbsum/4ni7 PDBsum]</span></td></tr>
	</table>		</table>
	== Disease ==		== Disease ==
Line 20:		Line 21:
	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>		From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
	</div>		</div>
		+	<div class="pdbe-citations 4ni7" style="background-color:#fffaf0;"></div>

	==See Also==		==See Also==
Line 28:		Line 30:
	</StructureSection>		</StructureSection>
	[[Category: Human]]		[[Category: Human]]
-	[[Category: Clifton, M]]	+	[[Category: Clifton, M C]]
	[[Category: Davies, D]]		[[Category: Davies, D]]
	[[Category: Edwards, T]]		[[Category: Edwards, T]]

OCA at 09:39, 5 January 2015

OCA — Mon, 05 Jan 2015 09:39:24 GMT

←Older revision		Revision as of 09:39, 5 January 2015
Line 1:		Line 1:
-	~~{{STRUCTURE_4ni7\| PDB=4ni7 \| SCENE= }}~~	+	==Crystal structure of human interleukin 6 in complex with a modified nucleotide aptamer (SOMAMER SL1025)==
-	===Crystal structure of human interleukin 6 in complex with a modified nucleotide aptamer (SOMAMER SL1025)===	+	<StructureSection load='4ni7' size='340' side='right' caption='[[4ni7]], [[Resolution\|resolution]] 2.40Å' scene=''>
-	~~{{ABSTRACT_PUBMED_24415767}}~~	+	== Structural highlights ==
-		+	<table><tr><td colspan='2'>[[4ni7]] is a 2 chain structure with sequence from [http://en.wikipedia.org/wiki/Human Human]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4NI7 OCA]. For a <b>guided tour on the structure components</b> use [http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4NI7 FirstGlance]. <br>
-	==Disease==	+	</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand\|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=NA:SODIUM+ION'>NA</scene></td></tr>
		+	<tr id='NonStdRes'><td class="sblockLbl"><b>[[Non-Standard_Residue\|NonStd Res:]]</b></td><td class="sblockDat"><scene name='pdbligand=2JU:2-DEOXY-5-[(NAPHTHALEN-1-YLMETHYL)CARBAMOYL]URIDINE+5-(DIHYDROGEN+PHOSPHATE)'>2JU</scene>, <scene name='pdbligand=A2M:2-O-METHYLADENOSINE+5-(DIHYDROGEN+PHOSPHATE)'>A2M</scene>, <scene name='pdbligand=DUZ:5-(BENZYLCARBAMOYL)-2-DEOXYURIDINE+5-(DIHYDROGEN+PHOSPHATE)'>DUZ</scene>, <scene name='pdbligand=OMC:O2-METHYLYCYTIDINE-5-MONOPHOSPHATE'>OMC</scene>, <scene name='pdbligand=OMG:O2-METHYLGUANOSINE-5-MONOPHOSPHATE'>OMG</scene>, <scene name='pdbligand=UPE:2-DEOXY-5-[(2-PHENYLETHYL)CARBAMOYL]URIDINE+5-(DIHYDROGEN+PHOSPHATE)'>UPE</scene></td></tr>
		+	<tr id='gene'><td class="sblockLbl"><b>[[Gene\|Gene:]]</b></td><td class="sblockDat">IL6, IFNB2 ([http://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?mode=Info&srchmode=5&id=9606 HUMAN])</td></tr>
		+	<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4ni7 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4ni7 OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4ni7 RCSB], [http://www.ebi.ac.uk/pdbsum/4ni7 PDBsum]</span></td></tr>
		+	</table>
		+	== Disease ==
	[[http://www.uniprot.org/uniprot/IL6_HUMAN IL6_HUMAN]] Genetic variations in IL6 are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:[http://omim.org/entry/604302 604302]]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis. Note=A IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in HIV-infected men.		[[http://www.uniprot.org/uniprot/IL6_HUMAN IL6_HUMAN]] Genetic variations in IL6 are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:[http://omim.org/entry/604302 604302]]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis. Note=A IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in HIV-infected men.
-		+	== Function ==
-	==Function==	+
	[[http://www.uniprot.org/uniprot/IL6_HUMAN IL6_HUMAN]] Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation Acts on B-cells, T-cells, hepatocytes, hematopoietic progenitor cells and cells of the CNS. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance.		[[http://www.uniprot.org/uniprot/IL6_HUMAN IL6_HUMAN]] Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation Acts on B-cells, T-cells, hepatocytes, hematopoietic progenitor cells and cells of the CNS. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance.
		+	<div style="background-color:#fffaf0;">
		+	== Publication Abstract from PubMed ==
		+	IL-6 is a secreted cytokine that functions through binding two cell surface receptors, IL-6Ralpha and gp130. Due to its involvement in the progression of several chronic inflammatory diseases, IL-6 is a target of pharmacologic interest. We have recently identified a novel class of ligands called SOMAmers (Slow Off-rate Modified Aptamers) that bind IL-6 and inhibit its biological activity. SOMAmers exploit the chemical diversity of protein-like side chains assembled on flexible nucleic acid scaffolds, resulting in an expanded repertoire of intra- and intermolecular interactions not achievable with conventional aptamers. Here we report the co-crystal structure of a high-affinity SOMAmer (Kd=0.20 nM) modified at the 5-position of deoxyuridine in a complex with IL-6. The SOMAmer, comprised of a G-quartet domain and a stem-loop domain, engages IL-6 in a clamp-like manner over an extended surface exhibiting close shape complementarity with the protein. The interface is characterized by substantial hydrophobic interactions overlapping the binding surfaces of the IL-6Ralpha and gp130 receptors. The G-quartet domain retains considerable binding activity as a disconnected autonomous fragment (Kd=270 nM). A single substitution from our diverse modified nucleotide library leads to a 37-fold enhancement in binding affinity of the G-quartet fragment (Kd=7.4 nM). The ability to probe ligand surfaces in this manner is a powerful tool in the development of new therapeutic reagents with improved pharmacologic properties. The SOMAmer:IL-6 structure also expands our understanding of the diverse structural motifs achievable with modified nucleic acid libraries and elucidates the nature with which these unique ligands interact with their protein targets.

-	~~==About this~~ Structure==	+	Crystal Structure of Interleukin-6 in Complex with a Modified Nucleic Acid Ligand.,Gelinas AD, Davies DR, Edwards TE, Rohloff JC, Carter JD, Zhang C, Gupta S, Ishikawa Y, Hirota M, Nakaishi Y, Jarvis TC, Janjic N J Biol Chem. 2014 Jan 12. PMID:24415767<ref>PMID:24415767</ref>
-	~~[[4ni7]] is~~ a ~~2 chain structure~~. ~~Full crystallographic information is available from [http~~://~~oca~~.~~weizmann~~.ac.il/~~oca-bin/ocashort?id=4NI7 OCA].~~	+
		+	From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br>
		+	</div>

	==See Also==		==See Also==
	*[[Interleukin\|Interleukin]]		*[[Interleukin\|Interleukin]]
-		+	== References ==
-	==~~Reference~~==	+	<references/>
-	~~<ref group="xtra">PMID:024415767</ref>~~<references ~~group="xtra"~~/><~~references~~/>	+	__TOC__
-	[[Category: Clifton, M.]]	+	</StructureSection>
-	[[Category: Davies, D.]]	+	[[Category: Human]]
-	[[Category: Edwards, T.]]	+	[[Category: Clifton, M]]
-	[[Category: Gelinas, A.]]	+	[[Category: Davies, D]]
-	[[Category: Jarvis, T.]]	+	[[Category: Edwards, T]]
		+	[[Category: Gelinas, A]]
		+	[[Category: Jarvis, T]]
	[[Category: Cytokine-dna complex]]		[[Category: Cytokine-dna complex]]
	[[Category: Interleukin-6]]		[[Category: Interleukin-6]]

OCA at 04:56, 9 April 2014

OCA — Wed, 09 Apr 2014 04:56:39 GMT

←Older revision		Revision as of 04:56, 9 April 2014
Line 11:		Line 11:
	==About this Structure==		==About this Structure==
	[[4ni7]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4NI7 OCA].		[[4ni7]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4NI7 OCA].
		+
		+	==See Also==
		+	*[[Interleukin\|Interleukin]]

	==Reference==		==Reference==

OCA at 03:37, 13 February 2014

OCA — Thu, 13 Feb 2014 03:37:52 GMT

←Older revision		Revision as of 03:37, 13 February 2014
Line 1:		Line 1:
	{{STRUCTURE_4ni7\| PDB=4ni7 \| SCENE= }}		{{STRUCTURE_4ni7\| PDB=4ni7 \| SCENE= }}
	===Crystal structure of human interleukin 6 in complex with a modified nucleotide aptamer (SOMAMER SL1025)===		===Crystal structure of human interleukin 6 in complex with a modified nucleotide aptamer (SOMAMER SL1025)===
		+	{{ABSTRACT_PUBMED_24415767}}

	==Disease==		==Disease==
Line 10:		Line 11:
	==About this Structure==		==About this Structure==
	[[4ni7]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4NI7 OCA].		[[4ni7]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4NI7 OCA].
		+
		+	==Reference==
		+	<ref group="xtra">PMID:024415767</ref><references group="xtra"/><references/>
	[[Category: Clifton, M.]]		[[Category: Clifton, M.]]
	[[Category: Davies, D.]]		[[Category: Davies, D.]]

OCA at 07:05, 22 January 2014

OCA — Wed, 22 Jan 2014 07:05:00 GMT

←Older revision		Revision as of 07:05, 22 January 2014
Line 1:		Line 1:
-	~~'''Unreleased~~ structure~~'''~~	+	{{STRUCTURE_4ni7\| PDB=4ni7 \| SCENE= }}
		+	===Crystal structure of human interleukin 6 in complex with a modified nucleotide aptamer (SOMAMER SL1025)===

-	~~The~~ entry ~~4ni7 is ON HOLD~~ ~~until Paper Publication~~	+	==Disease==
		+	[[http://www.uniprot.org/uniprot/IL6_HUMAN IL6_HUMAN]] Genetic variations in IL6 are associated with susceptibility to rheumatoid arthritis systemic juvenile (RASJ) [MIM:[http://omim.org/entry/604302 604302]]. An inflammatory articular disorder with systemic-onset beginning before the age of 16. It represents a subgroup of juvenile arthritis associated with severe extraarticular features and occasionally fatal complications. During active phases of the disorder, patients display a typical daily spiking fever, an evanescent macular rash, lymphadenopathy, hepatosplenomegaly, serositis, myalgia and arthritis. Note=A IL6 promoter polymorphism is associated with a lifetime risk of development of Kaposi sarcoma in HIV-infected men.

-	~~Authors~~: ~~Davies, D~~.~~, Edwards~~, T., ~~Gelinas~~, A.~~, Jarvis, T~~.~~, Clifton, M~~.	+	==Function==
		+	[[http://www.uniprot.org/uniprot/IL6_HUMAN IL6_HUMAN]] Cytokine with a wide variety of biological functions. It is a potent inducer of the acute phase response. Plays an essential role in the final differentiation of B-cells into Ig-secreting cells Involved in lymphocyte and monocyte differentiation. It induces myeloma and plasmacytoma growth and induces nerve cells differentiation Acts on B-cells, T-cells, hepatocytes, hematopoietic progenitor cells and cells of the CNS. Also acts as a myokine. It is discharged into the bloodstream after muscle contraction and acts to increase the breakdown of fats and to improve insulin resistance.

-	~~Description: Crystal~~ structure ~~of human interleukin 6 in~~ complex ~~with a modified nucleotide aptamer (SOMAMER SL1025)~~	+	==About this Structure==
		+	[[4ni7]] is a 2 chain structure. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4NI7 OCA].
		+	[[Category: Clifton, M.]]
		+	[[Category: Davies, D.]]
		+	[[Category: Edwards, T.]]
		+	[[Category: Gelinas, A.]]
		+	[[Category: Jarvis, T.]]
		+	[[Category: Cytokine-dna complex]]
		+	[[Category: Interleukin-6]]

OCA at 09:49, 27 November 2013

OCA — Wed, 27 Nov 2013 09:49:22 GMT

←Older revision		Revision as of 09:49, 27 November 2013
Line 1:		Line 1:
	'''Unreleased structure'''		'''Unreleased structure'''

-	The entry 4ni7 is ON HOLD	+	The entry 4ni7 is ON HOLD until Paper Publication

	Authors: Davies, D., Edwards, T., Gelinas, A., Jarvis, T., Clifton, M.		Authors: Davies, D., Edwards, T., Gelinas, A., Jarvis, T., Clifton, M.

	Description: Crystal structure of human interleukin 6 in complex with a modified nucleotide aptamer (SOMAMER SL1025)		Description: Crystal structure of human interleukin 6 in complex with a modified nucleotide aptamer (SOMAMER SL1025)

OCA at 12:58, 20 November 2013

OCA — Wed, 20 Nov 2013 12:58:30 GMT

←Older revision		Revision as of 12:58, 20 November 2013
Line 3:		Line 3:
	The entry 4ni7 is ON HOLD		The entry 4ni7 is ON HOLD

-	Authors: Davies, ~~Doug~~, Edwards, ~~Thomas~~, Gelinas, ~~Amy~~, Jarvis, ~~Thale~~, Clifton, ~~Matt~~	+	Authors: Davies, D., Edwards, T., Gelinas, A., Jarvis, T., Clifton, M.

-	Description: ~~CRYSTAL STRUCTURE OF HUMAN INTERLEUKIN~~ 6 ~~IN COMPLEX WITH A MODIFIED NUCLEOTIDE APTAMER~~ (SOMAMER SL1025)	+	Description: Crystal structure of human interleukin 6 in complex with a modified nucleotide aptamer (SOMAMER SL1025)

OCA: Protected "4ni7" [edit=sysop:move=sysop]

OCA — Wed, 13 Nov 2013 07:50:16 GMT

Protected "4ni7" [edit=sysop:move=sysop]

←Older revision

Revision as of 07:50, 13 November 2013